semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain, Mechanical Spinal Stenosis Nerve Root Disorder Radiculopathy, Cervical Benign Hypermobility Syndrome Clinical diagnosis of axial back pain (neck, mid-back, lower back) or pain radiating to the extremity, with suspected diagnosis of a specific pain generator amenable to a pain procedure, including disorders of the nerves, joints, and muscles as listed immediately below Clinical decision to schedule patient for a pain procedure, including procedures targeting the following disorders Facet arthropathy: intra-articular facet joint injection, medial branch block, medial branch radiofrequency ablation Sacroiliac joint dysfunction: sacroiliac joint injection, lateral branch block, lateral branch radiofrequency ablation Myofascial pain syndrome: trigger point injection Radiculopathy, spinal stenosis, or herniated nucleus pulposus: epidural steroid injection, selective nerve root block Piriformis syndrome: piriformis injection Greater trochanteric bursitis: greater trochanteric bursa injection Able to provide HIPAA authorization to share prior medical records/imaging  Previous diagnosis of cancer Currently pregnant Previously enrolled for the same procedure or the same pain generator site. (For example, this would a patient who had an intra-articular facet joint injection at the right L5/S1 if: 1) he had the same injection 3 months ago and was enrolled at that time, or 2) the patient was already enrolled for a medial branch block at the right L5 and sacral ala, as this targets the same facet joint.) Inability or unwillingness of subject or legal guardian/representative to give informed consent (e.g., ward of the state)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-49.0,  Stunting in Under-2 Children All new pregnancies in the selected clusters Eligible woman is resident of the study area Gestational age ≤125 days Possible pregnant woman can identify her last menstrual period (LMP)  Similar nutrition interventions currently being implemented by either public or non-government agency in the selected cluster The cluster is too hard to reach and accessibility of the cluster is highly constrained by geographical impediments The cluster includes tea gardens. Communities in tea gardens comprise of unique ethnicity, culture and lifestyle for which our intervention is not customized
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Urothelial Carcinoma Urothelial Cancer Lung Neoplasms Small Cell Lung Cancer Prostate Cancer Phase I Patients must have advanced solid tumor that is resistant or refractory to standard therapy A minimum of 2 weeks will be required from any prior therapy, including chemotherapy, immunotherapy and/or radiation. In addition, recovery to Grade less than or equal to 1 from all reversible toxicities related to prior therapy is required at study entry Patients do not need to have measurable disease to enroll on phase I Age greater than or equal 18 years ECOG performance status less than or equal to 2 Patients with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the patient is off steroids or is on a stable dose of steroids. Patients with brain metastases should not require use of enzyme-inducing antiepileptic drugs (e.g., carbamazepine, phenytoin, or phenobarbital) within 14 days before first dose and during study. Use of newer antiepileptics that do not produce enzyme induction drug-drug interactions (DDIs) is allowed Patients must have normal organ and marrow function as defined below leukocytes greater than or equal to 3,000/mcL absolute neutrophil count >1,500/mcL without growth factor support
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthralgia Arthritis Females and males aged ≥ 18 years at time of consent ACPA (with or without RF) Joint pain (hand, feet, knee, shoulder or elbow) present for at least 6 weeks prior to or in past history Presence of synovitis (synovialitis or tenosynovitis) or osteitis in MRI of the dominant hand at baseline Women of childbearing potential or men capable of fathering children must be using effective contraception during treatment with abatacept and up to 14 weeks after the last dose of abatacept treatment Must understand and voluntarily sign an informed consent form including written consent for data protection Must be able to adhere to the study visit schedule and other protocol requirements  Presence of arthritis in hand, feet, knee, shoulder or elbow joints defined as swelling Current treatment with glucocorticoids conventional or biologic DMARDs Previous treatment with abatacept Investigational study drug within 4 weeks (or 5 half lives, whichever is longer) prior to randomization Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, SpA, Behcet disease, vasculitis or autoimmune hepatitis Any malignancy in the last 5 years Chronic infection such as latent TB (TB not adequately treated according to guidelines) or hepatitis B or C infection Immunocompromised or HIV-positive patients Uncontrolled severe concomitant disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain medically diagnosed with non-specific chronic low back pain4, 2. over 18 years old, 3. able to understand Dutch (spoken and written)  invasive surgery at the lumbar spine in the last 18 months (arthrodesis was excluded, microsurgery was allowed), 2. radiculopathy (uni or bilateral), 3. co-morbidities: paresis and/or sensory disturbances by neurological causes, diabetes mellitus, rheumatoid arthritis, an increase of pain of 3 points with a result of > 8/10 on the Numeric Pain Rating Scale (NPRS) in the last 48 hours, pregnancy, 4. ongoing compensation claims and/or (work)disability > 6 months, 5. rehabilitation/exercise therapy program for LBP in the past 6 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 3.0-8.0,  Pain All patients between the ages of 3-8 undergoing adenotonsillectomy for an indication of adenotonsillar hypertrophy who are scheduled for overnight 23 hour observation at CCHMC main campus  Patients with moderate to severe developmental delay will be excluded due to difficulties in scoring postoperative pain. In addition, those with allergies to Montelukast and those currently using Montelukast will be excluded. Those with moderate to severe cardiac, hepatic, pulmonary or renal disease will be excluded. All patients with a primary indication of chronic tonsillitis will be excluded. Those with active respiratory infections requiring cancellation of surgery will be excluded based on the Anesthesia services recommendations
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Patients treated in Meir Medical Center 2. Data on serum vitamin D values 3. 18 years old 4. Both sexes 5. Patient hereby declare that he\she agree to participate the clinical trial  Patient refuses to sign Informed Consent. 2. Patients without vitamin D values
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hypovitaminosis D Males or females, 18-70 years of age and self-identified as African-American or Black Pre-hypertension or hypertension (well controlled see below) If a potential study patient is not on treatment their SBP must be > 120 mmHg, or DBP > 80 mmHg Whether on treatment or not SBP must be <160 mmHg and DBP must be < 100 mmHg (BP is not an outcome. Controlled BP is for participant safety) Screening Vitamin D (D2 and D3 level) >5 and < 25 ng/ml (recommended normal level is > 30 ng/ml) Body mass index (BMI) > 25 kg/m2 and < 45 kg/m2 Any female of non-childbearing potential, including any female who has had a hysterectomy has had a bilateral oophorectomy  Concurrent Disease Poorly controlled high blood pressure (SBP ≥160 mmHg or DBP ≥ 100 mmHg) Poorly controlled diabetes (HbA1c >8.5%) Screening Vitamin D (D2 and D3 level) < 5 or > 25 ng/ml (recommended normal level is > 30 ng/ml) Estimated glomerular filtration rate (eGFR) < 45 ml/min Evidence of disease that could result in hypercalcemia History of kidney stones (less than one year prior to screening) History of drug, alcohol, or illicit substance abuse (within the past 6 months) History of another chronic disease which the investigator feels should preclude the subject from entering the study (e.g. cancer, immunologic disorder) Liver function tests (LFTs) greater than twice the upper limit of normal
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 45.0-55.0,  Arthralgia age between 45 and 55 years chronic arthralgia related to climacteric regular mammography and pap smear test in the last twelve months availability to attend hormone replacement therapy maximum of ten years of amenorrhea according to the of Stages of Reproductive Aging Workshop (STRAW) without use of hormone replacement therapy, at least, previous six months no contraindication to hormone replacement therapy (current or past of breast and / or cervical cancer, severe current or recent heart disease, thromboembolism, hypertension with no control, metabolic diseases (but stable thyroid disease) and endometrial hyperplasia to be enlightened Informed consent  autoimmune diseases visceral pain (chronic pelvic pain, dyspareunia, irritable bowel syndrome) systemic diseases (rheumatic, neurological, oncology, sexually transmitted infection) body mass index of 30 or greater soy diet abuse of alcohol and drugs large surgeries
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Total Hip Arthroplasty Primary total hip arthroplasty (THA)  Revision cases Uncontrolled bleeding tendency (prothrombin conc. Less than 70%) History of deep venous thrombosis Sever liver impairment (liver failure) Sever renal impairment (S. creatinine more than 3)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Vitamin D Status No drug use BMI< 25 kg/m2 Do not eat fish more than 2 x weekly Not donated blood within 3 months No Holiday plans in Winter 2006-2007  Any disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Massive Transfusion Trauma Cardiothoracic Surgery Gastrointestinal Bleeding Vascular Surgery Obstetric Bleeding Liver Transplant aged 18 years or over or more units of red blood cells in any 4 hour period  nil
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Critical Illness 18 years or older. 2. Both male and female 3. Within 24 hours from admission. 4. Having 25 -Hydroxyvitamin D level of 12 ng/ml or lower  Pregnant or lactating females. 2. Do not resuscitate (DNR) status or comfort measures only 3. No consent 4. Severely impaired gastrointestinal functions (e.g, paralytic ileus, continuous nasogastric tube drainage, strict nil per oral no medication, malabsorption syndrome, chronic diarrhea etc) 5. History of renal stones within past year 6. Past history of hypercalcemia, tuberculosis or sarcoidosis. 7. Baseline serum total calcium ≥10.6 mg/dl or ionized serum calcium ≥ 5.4 mg/dl
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Disorder of Hip Region Surgeons, nurses, and other staff involved in direct care of patients undergoing hip or knee arthroplasty Staff had to be affiliated with one of 20 hospitals selected at random from among all hospitals in each of 10 states that performed a minimum of 100 hip or knee arthroplasties for Medicare beneficiaries  Per diem staff
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Neoplasm, Trophoblastic Gestational Trophoblastic Disease Hydatidiform Mole Hydatidiform Mole, Invasive Patients are eligible if they have a histologically proven trophoblastic disease, or a diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG  none
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 35.0-55.0,  Deficiency of Vitamin D3 Women 35 years old Women who spoke Arabic language fluently, and Women who were willing to fill a 24-hour questionnaire and provide a serum sample for measurements  Women < 35 years old or > 55 years old
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 17.0-49.0,  Premature Birth For Adolescent girls: 1. Permanent resident of the study area (Adolescents who are usual residents of the households and living or intend to live in the area for 6 or more months) 2. Aged between 15-17 years at the time of recruitment 3. Parent or legal guardian is present at the time of recruitment and is willing to give assent for the adolescent's participation For Recently married women: 1. Permanent resident of the study area (Recently married women who are usual residents of the households living or intend to live in the area for 6 or more months) 2. Married within the past two years with no children or a single child  For Adolescent girls: 1. Married at the time of recruitment 2. Parent or the legal guardian is mentally/physically unable to give assent For Recently married women: 1. Pregnant or exclusively breastfeeding at the time of recruitment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-70.0,  Healthy, Postmenopausal Women to 70 years of age Lack of menses in the last year and FSH 23-116.3 mlU/mL Subject is willing and able to comply with the study protocols Subject is willing participate in all study procedures BMI 18.5 9 kg/m2 Weight ≥ 110 pounds  BMI < 18.5 kg/m2 BMI ≥ 35 kg/m2 Dislike or allergy for dried plums Self-reported use of daily anticoagulation agents including aspirin, NSAIDs Self-reported use of oral cortisone or other immunosuppressive agents Self-reported underlying neoplasia or immunological disease Vegan, Vegetarians, food faddists or those consuming a non-traditional diet • Alcohol consumption > 3 drinks/week (i.e. 1 bottle of beer, ½ glass of wine, and 1 shot of hard liquor) Fruit consumption ≥ 2 cups/day Vegetable consumption ≥ 3 cups/day for females Fatty Fish ≥ 3 times/week
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  MPN (Myeloproliferative Neoplasms) MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc) Willing and able to provide written informed consent Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Under the supervision of a physician for the current care of MF or ET  Individuals who are participating in blinded investigational drug studies Individuals who are participating in Incyte investigational/interventional drug trials (company or investigator-sponsored studies) until they have completed the 30-day end of study visit Life expectancy ≤ 6 months Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis